^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:LYT-200 (Galectin-9 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Businesswire
    Title:

    PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers

    Published date:
    04/11/2024
    Excerpt:
    PureTech Health plc...announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for LYT-200 in combination with anti-PD1 therapy for the treatment of recurrent/metastatic head and neck squamous cell carcinomas (“head and neck cancers”).